| Updated:
ValiRx sees revenues rise
ValiRx, the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has seen revenue for the year increased to £177,297, up from £29,326 in 2009, in its final results. The company pointed to solid progress with pre-clinical programmes of leading therapeutic compounds and the successful $1m (£608m) disposal of a non-core diagnostic subsidiary.